Fusion Antibodies teams with Analytics Engines on machine learning, AI platform

GloballData, artificial intelligence (AI)
Fusion Antibodies is partnering with Analytics Engines to incorporate machine learning and AI into its CDRx humanization platform. (GlobalData)

U.K.-based CRO Fusion Antibodies is partnering with Analytics Engines to incorporate machine learning and artificial intelligence into its CDRx humanization platform.

The platform can perform multiple virtual experiments using machine learning and AI with panels of selected antibodies. The goal of the partnership is to boost Fusion’s platform in order for the company to meet its goal of reducing development costs and increasing the speed of clinical timelines.

“We want to keep differentiating our product to make sure it’s the best humanization platform in the world,” Paul Kerr, Fusion’s chief executive, said in a statement. “Collaborating with Analytics Engines will allow us to drive our quality and add more certainty and manufacturability to the products.”


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The company’s CDRx platform builds on traditional clinical data repository (CDR) grafting techniques by in silico grafting parental CDRs into mature human antibody frameworks. It can screen a database of about 100,000 use antibody sequences as well as generate full-length humanized antibodies that can be refined to a level that further resembles human antibodies.

“Using our expertise in machine learning and AI, Fusion Antibodies will be able to create ML models to continually improve their antibody humanization process,” Aislinn Rice, Ph.D., Analytics Engines’ CEO, said in a statement.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.